Patients with TSC2 variations may benefit from mTOR inhibitors like everolimus, which have demonstrated a >50% reduction in seizure frequency in TSC-related epilepsy patients (Krueger et al., 2013). Here, TSC2 is linked to tuberous sclerosis.